The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
Open accessAbstract
INTRODUCTION: New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients. METHODS AND FINDINGS: Published 2015 ex-factory prices for a 12-wk course of treatment were provided by the Pharma Price Information (PPI) service of the Austrian public health institute Gesundheit Österreich GmbH or were obtained from national government or drug reimbursement authorities and recent press releases, where necessary. Prices in Organisation for Economic Co-operation and Development (OECD) member countries and select low- and middle-income countries were converted to US dollars using period average exchange rates and were adjusted for purchasing power parity (PPP). We analysed prices compared to national economic performance and estimated market size and the cost of these drugs in terms of countries' annual total pharmaceutical expenditure (TPE) and in terms of the duration of time an individual would need to work to pay for treatment out of pocket. Patient affordability was calculated using 2014 OECD average annual wages, supplemented with International Labour Organization median wage data where necessary. All data were compiled between 17 July 2015 and 25 January 2016. For the base case analysis, we assumed a 23% rebate/discount on the published price in all countries, except for countries with special pricing arrangements or generic licensing agreements. The median nominal ex-factory price of a 12-wk course of sofosbuvir across 26 OECD countries was US$42,017, ranging from US$37,729 in Japan to US$64,680 in the US. Central and Eastern European countries had higher PPP-adjusted prices than other countries: prices of sofosbuvir in Poland and Turkey (PPP$101,063 and PPP$70,331) and of ledipasvir/sofosbuvir in Poland (PPP$118,754) were at least 1.09 and 1.63 times higher, respectively than in the US (PPP$64,680 and PPP$72,765). Based on PPP-adjusted TPE and without the cost of ribavirin and other treatment costs, treating the entire HCV viraemic population with these regimens at the PPP-adjusted prices with a 23% price reduction would amount to at least one-tenth of current TPE across the countries included in this study, ranging from 10.5% of TPE in the Netherlands to 190.5% of TPE in Poland. In 12 countries, the price of a course of sofosbuvir without other costs was equivalent to 1 y or more of the average annual wage of individuals, ranging from 0.21 y in Egypt to 5.28 y in Turkey. This analysis relies on the accuracy of price information and infection prevalence estimates. It does not include the costs of diagnostic testing, supplementary treatments, treatment for patients with reinfection or cirrhosis, or associated health service costs. CONCLUSIONS: Current prices of these medicines are variable and unaffordable globally. These prices threaten the sustainability of health systems in many countries and prevent large-scale provision of treatment. Stakeholders should implement a fairer pricing framework to deliver lower prices that take account of affordability. Without lower prices, countries are unlikely to be able to increase investment to minimise the burden of hepatitis C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,707
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
International Labour Organization
(2022) · Permanent Missions to the United Nations · doi:10.18356/9789210018289c229 · Cited by 4,331
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Evolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Bank, W. (2015) · The World Bank Group A to Z 2016 · doi:10.1596/978-1-4648-0484-7_world_development_indicators · Cited by 761
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1053/jhep.2002.36810 · Cited by 727
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401 · cited 7×
“[17] Impact: underestimates total expenditure because not all countries would receive such large discounts.”
BackgroundMethodInfluentialChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
Hoen, E. '., Berger, J., Calmy, A., & Moon, S. (2011) · Journal of the International AIDS Society · doi:10.1186/1758-2652-14-15 · Cited by 334
Grebely, J., Prins, M., Hellard, M., Cox, A. L., Osburn, W. O., Lauer, G., Page, K., Lloyd, A. R., & Dore, G. J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70010-5 · Cited by 230
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu012 · Cited by 216 · cited 1×
“A recent study estimated the cost of production of sofosbuvir to be US$68–US$136 for a 12-wk course of treatment based on the same manufacturing methods used in the large-scale generic production of HIV/AIDS medicines [12], and its findings have not been challenged.”
MethodWaning, B., Diedrichsen, E., & Moon, S. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-35 · Cited by 154
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Tefferi, A., Kantarjian, H. M., Rajkumar, S. V., Baker, L. H., Abkowitz, J., Adamson, J. W., Advani, R. H., Allison, J. P., Antman, K. H., Bast, R. C., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.001 · Cited by 145
Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries
Cameron, A., Bansal, A., Dua, T., Hill, S. R., Moshé, S. L., Mantel-Teeuwisse, A. K., & Saxena, S. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03446.x · Cited by 126
Self-citationMixed HCV infection and reinfection in people who inject drugs—impact on therapy
Cunningham, E. B., Applegate, T. L., Lloyd, A. R., Dore, G. J., & Grebely, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.36 · Cited by 105
Disparity in market prices for hepatitis C virus direct-acting drugs
Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., & Hamid, S. S. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00156-4 · Cited by 83
Discounts and rebates granted to public payers for medicines in European countries.
Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J., & Bucsics, A. (2012) · PubMed Central · Cited by 77
Self-citationFeuerstadt, P., Bunim, A. L., Garcia, H., Karlitz, J. J., Massoumi, H., Thosani, A. J., Pellecchia, A., Wolkoff, A. W., Gaglio, P. J., & Reinus, J. F. (2009) · Hepatology · doi:10.1002/hep.23429 · Cited by 66
Jakubiak-Lasocka, J., & Jakubczyk, M. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.06.008 · Cited by 50
Income Level and Drug Related Harm among People Who Use Injection Drugs in a Canadian Setting
Long, C., Debeck, K., Feng, C., Montaner, J., Wood, E., & Kerr, T. (2013) · The International journal on drug policy · doi:10.1016/j.drugpo.2013.11.011 · Cited by 49
Bichoupan, K., Martel‐Laferrière, V., Sachs, D. M., Ng, M., Schonfeld, E. A., Pappas, A., Crismale, J. F., Stivala, A. C., Khaitova, V., Gardenier, D., et al. (2014) · Hepatology · doi:10.1002/hep.27340 · Cited by 40
Skoupá, J., Annemans, L., & Hájek, P. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.06.003 · Cited by 31
Ollendorf, D. A., Tice, J. A., & Pearson, S. D. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2151 · Cited by 23
Wirtz, V. J., Santa‐Ana‐Téllez, Y., Trout, C., & Kaplan, W. A. (2012) · Health Policy and Planning · doi:10.1093/heapol/czs011 · Cited by 12
Cited by
Cost–effectiveness thresholds: pros and cons
Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164418 · Cited by 783
Self-citationEssential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Assetization: Turning Things into Assets in Technoscientific Capitalism
(2020) · The MIT Press eBooks · doi:10.7551/mitpress/12075.001.0001 · Cited by 421
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
Metadata
- Authors
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-31
- Volume
- 13
- Issue
- 5
- Pages
- e1002032
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2416145228
- Cited by
- 255
- References
- 31
- FWCI
- 90.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.